Clinical trials: Neuroendocrine Neoplasms (Tumours)
Melanoma
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT06190951
- Testing
- cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab
- Where
- 104 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when…
- Trial name
- NCT00849875
- Testing
- Immunotherapeutic GSK2132231A, Dacarbazine
- Where
- 14 sites in Belgium, France
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Melanoma
OH2 Injection in Melanoma
To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC)…
- Trial name
- NCT05868707
- Testing
- OH2, Salvage chemotherapy or best supportive care
- Where
- 30 sites in China
- Volunteers
- 340 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Merkel Cell Carcinoma
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with…
- Trial name
- MERKLIN2 (NCT04393753)
- Testing
- domatinostat in combination with avelumab
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 19 people
- Sponsor
- 4SC AG
Gastroenteropancreatic Neuroendocrine Tumor G3
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.
- Trial name
- NCT03457844
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Neuroendocrine Prostate Cancer
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide…
- Trial name
- NCT06379217
- Testing
- [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma and Brain Metastases
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
This is a global, multi-centre, open-label, study of GSK2118436 conducted in up to 30 evaluable subjects with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain.
- Trial name
- NCT01978236
- Testing
- Dabrafenib 150 mg, Trametinib 2.0 mg
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Unresectable Melanoma, Metastatic Melanoma
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or…
- Trial name
- CheckMate 069 (NCT01927419)
- Testing
- Nivolumab, Ipilimumab
- Where
- 21 sites in United States, France
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Refractory Melanoma
Study of CP-675,206 in Refractory Melanoma
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes.
- Trial name
- NCT00254579
- Testing
- CP-675,206
- Where
- 65 sites in United States, Argentina and 7 more
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
CASA Intervention, Usual Care
Beyond Psychological Distress: Implementation of a Dyadic Behavioral Intervention Targeting Neuroendocrine and mRNA Translational Pathways in Late-Stage Breast Cancer
Specific Aim 1: Determine the effect of CASA on psychological distress (primary outcome) and on neuroendocrine, inflammatory, and translational control measures (secondary and exploratory outcomes) in LSBC-PR patients and…
- Trial name
- Beyond ID (NCT07828288)
- Testing
- The Caregivers-Patients Support to Cope with Advanced Cancer (CASA) is a five-session, manualized, meaning-centered psychotherapy developed for Puerto Rican patients and caregivers coping with advance, Control Condition. Includes CBT as the primary treatment approach for cancer patients and it is considered the usual care approach in these clinics, as well as one of the primar
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Ponce Medical School Foundation, Inc.
Prostate Cancer, Melanoma
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the…
- Conditions
- Prostate Cancer, Melanoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT00818480
- Testing
- YM155
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Inc
Solid Tumor
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
- Trial name
- NCT01607905
- Testing
- Selinexor, Acetaminophen
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 192 people
- Sponsor
- Karyopharm Therapeutics Inc
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Melanoma
MElanoma Research Lymph Node Prediction Implementation National_001
MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
- Trial name
- MERLIN_001 (NCT04759781)
- Where
- 9 sites in United States
- Volunteers
- 1,820 people
- Sponsor
- SkylineDx
Merkel Cell Carcinoma
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in…
- Trial name
- NCT03787602
- Testing
- KRT-232, Avelumab
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 115 people
- Sponsor
- Kartos Therapeutics, Inc.
Choroidal Melanoma, Indeterminate Lesions
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- NCT07421739
- Testing
- Non-interventional, digital, patient-reported, study
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Aura Biosciences
Stage III Melanoma, Stage IV Melanoma
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma
- Trial name
- NCT01026051
- Testing
- MKC1106-MT
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mannkind Corporation
Melanoma
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated…
- Trial name
- NCT06848088
- Testing
- Fianlimab+cemiplimab
- Where
- 11 sites in United States, Ireland
- Volunteers
- 48 people
- Sponsor
- Regeneron Pharmaceuticals
Colo-rectal Cancer, Stomach Cancer
Validation of MMS Test for Cancer Monitoring
The purpose of this study is the validation of MMS test to detect active tumor growth in different cancer types before and after therapy, as well as in the course of therapy and for subsequent relapse control compared to standard…
- Conditions
- Colo-rectal Cancer, Stomach Cancer, Melanoma, Sarcoma
- Trial name
- MMS-TM (NCT02113683)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- MedInnovation GmbH
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.